neutropen
patient
transplant
recipi
risk
number
lifethreaten
opportunist
infect
neither
patient
group
suffer
singl
specif
immunolog
deficit
subtl
blend
physic
immunolog
defect
evolv
time
judgment
manag
need
base
upon
knowledg
balanc
defect
time
infect
major
hematooncolog
center
transplant
unit
base
patient
manag
includ
infect
upon
agre
protocol
evid
base
becom
robust
recent
year
addit
nation
intern
guidelin
base
import
protocol
regularli
updat
take
account
local
variat
risk
organ
antimicrobi
sensit
invers
relationship
number
circul
neutrophil
risk
infect
establish
four
decad
ago
effect
becom
appar
absolut
neutrophil
count
less
l
risk
increas
consider
count
fall
l
patient
count
less
l
week
found
develop
infect
episod
criteria
enrol
febril
neutropenia
trial
usual
includ
neutrophil
count
less
l
patient
neutropen
follow
chemotherapi
leukemia
leukem
patient
present
neutropenia
chemotherapi
addit
neutrophil
patient
myelodysplast
syndrom
md
leukemia
particularli
acut
myeloid
leukemia
aml
may
impair
microbicid
activ
patient
receiv
chemotherapi
highrisk
relaps
leukemia
may
neutropen
week
longer
receiv
regimen
contain
fludarabin
undergo
standard
chemotherapi
lymphoma
solid
tumor
may
also
suffer
reduct
circul
neutrophil
rare
less
l
often
l
durat
neutropenia
often
less
day
patient
aplast
anemia
bone
marrow
transplant
bmt
recipi
fail
engraft
neutropenia
often
profound
prolong
normal
engraft
allogen
bmt
recipi
take
place
week
transplant
steadi
increas
number
peripher
blood
stem
cell
transplant
pbsct
perform
europ
autolog
pbsct
virtual
replac
autolog
bone
marrow
transplant
autolog
pbsct
recipi
shorter
durat
neutropenia
patient
undergo
allogen
bone
marrow
transplant
behav
essenti
like
neutropen
patient
earli
posttranspl
phase
remain
immunosuppress
year
even
without
complic
graftversushost
diseas
gvhd
caus
neutropenia
shown
box
pathogenesi
infect
patient
multifactori
often
consequ
breach
skin
oral
mucosa
plu
defect
cellular
humor
immun
defect
associ
specif
infect
tabl
lymphopenia
consequ
lymphoid
malign
treatment
associ
reactiv
intracellular
organ
mycobacteria
herp
virus
toxoplasma
gondii
pneumocysti
jirovecii
formerli
pneumocysti
carinii
patient
chronic
lymphoid
malign
receiv
immunosuppress
chemotherapi
bmt
recipi
impair
antibodi
product
predispos
infect
encapsul
organ
streptococcu
pneumonia
use
indwel
central
venou
cathet
mucos
damag
caus
chemotherapi
herp
simplex
viru
hsv
infect
allow
penetr
commens
flora
recent
year
chang
cytotox
chemotherapi
render
oropharynx
major
portal
entri
streptococci
likewis
splenectomi
undertaken
treatment
diagnosi
render
patient
suscept
infect
encapsul
organ
str
pneumonia
other
preexist
site
chronic
infect
middleear
diseas
bronchiectasi
may
act
reservoir
infect
organ
pseudomona
aeruginosa
ethnic
origin
foreign
travel
may
increas
exposur
infect
tuberculosi
malaria
strongyloidiasi
febril
episod
neutropen
patient
confirm
microbiolog
due
bacteremia
infect
gramposit
bacteria
especi
coagulaseneg
staphylococci
streptococci
increas
frequenc
past
two
decad
eortc
european
organis
research
treatment
cancer
participatori
center
incid
bacteremia
due
gramposit
organ
increas
increas
correl
escal
use
central
venou
cathet
develop
altern
highdos
chemotherapi
attend
mucos
better
prevent
gramneg
infect
howev
subsequ
trial
shown
fall
possibl
associ
declin
quinolon
prophylaxi
usag
associ
emerg
resist
recent
interest
find
cellwal
defici
mostli
gramposit
bacteria
may
respons
episod
neutropen
fever
bmt
recipi
gramneg
bacteria
continu
caus
seriou
episod
sepsi
infect
caus
enterobacteriacea
ps
aeruginosa
carri
mortal
oropharyng
candidosi
extrem
common
patient
receiv
prophylaxi
invas
candidosi
aspergillosi
account
fatal
infect
treat
acut
leukemia
invas
aspergillosi
import
infect
caus
death
childhood
acut
myeloid
leukemia
allogen
hematopoiet
stem
cell
transplant
hsct
recipi
risk
wide
rang
infect
base
upon
extent
exposur
degre
immunosuppress
autolog
hsct
recipi
also
risk
infect
although
lesser
degre
due
shorter
period
neutropenia
time
engraft
howev
patient
receiv
autograft
appear
similar
level
risk
allogen
hsct
recipi
cytomegaloviru
cmv
opportunist
infect
risk
summar
box
prevent
seriou
infect
goal
clinician
mani
year
strategi
prevent
acquisit
organ
provis
low
microbi
diet
use
higheffici
particul
air
hepa
filtrat
appear
import
profoundli
neutropen
patient
risk
aspergillosi
increasingli
emphas
recent
year
infect
hsct
recipi
vulner
tempor
categor
three
period
follow
transplant
preengraft
less
week
immedi
postengraft
week
month
late
postengraft
month
period
pathogen
immun
defect
associ
host
factor
hsct
recipi
illustr
figur
variou
trial
examin
efficaci
oral
nonabsorb
antibiot
although
number
flaw
sever
control
trial
show
benefit
combin
protect
environ
although
trimethoprimsulfamethoxazol
first
use
patient
acut
leukemia
prevent
pn
jirovecii
pneumon
also
reduc
incid
bacteri
infect
studi
demonstr
greatest
benefit
patient
prolong
neutropenia
reduct
gramneg
bacteri
infect
seen
howev
incid
side
effect
includ
bone
marrow
suppress
select
multiresist
organ
led
declin
use
indic
oral
quinolon
current
commonli
use
prophylact
antibacteri
agent
adult
patient
chemotherapyinduc
neutropenia
initi
oral
quinolon
ciprofloxacin
ofloxacin
norfloxacin
compar
number
studi
placebo
trimethoprimsulfamethoxazol
nonabsorb
antibiot
major
treat
patient
significantli
fewer
gramneg
bacteri
infect
delay
onset
fever
reduct
number
day
fever
importantli
reduct
mortal
demonstr
concern
quinolon
resist
increas
unit
led
discontinu
quinolon
prophylaxi
howev
initi
metaanalysi
show
signific
problem
recent
eortc
health
protect
agenc
hpa
data
support
find
sequenti
studi
shown
combin
ciprofloxacin
colistin
associ
signific
chang
quinolon
resist
period
howev
recent
metaanalysi
evalu
random
trial
afebril
neutropen
patient
major
hematolog
malign
compar
antibiot
prophylaxi
placebo
intervent
anoth
antibiot
class
shown
signific
reduct
risk
death
compar
placebo
treatment
rel
risk
rr
surviv
benefit
substanti
analysi
limit
fluoroquinolon
fluoroquinolon
prophylaxi
reduc
risk
allcaus
mortal
rr
ci
well
infectionrel
mortal
fever
clinic
document
infect
microbiolog
document
infect
although
signific
increas
resist
bacteria
fluoroquinolon
prophylaxi
length
observ
may
insuffici
detect
emerg
resist
bacteria
prophylact
antibiot
associ
increas
risk
advers
event
follow
metaanalysi
two
random
doubleblind
placebocontrol
trial
levofloxacin
prophylaxi
neutropen
patient
undergo
chemotherapi
perform
levofloxacin
similar
activ
gramneg
bacteria
comparison
ciprofloxacin
except
pseudomonad
howev
improv
activ
certain
gramposit
pathogen
includ
streptococci
first
trial
evalu
levofloxacin
prophylaxi
initi
chemotherapi
neutrophil
recoveri
higherrisk
mainli
inpati
adult
leukaem
stem
cell
transplant
patient
chemotherapyinduc
neutropenia
expect
last
day
second
trial
outpati
set
evalu
levofloxacin
prophylaxi
chemotherapi
solid
tumor
lymphoma
patient
anticip
period
neutropenia
day
less
effect
prophylaxi
similar
patient
group
two
trial
mortal
toler
trial
fail
demonstr
signific
surviv
benefit
prophylaxi
result
reflect
previou
metaanalys
review
trial
demonstr
number
need
treat
prevent
one
death
caus
patient
patient
expect
durat
neutropenia
day
decis
whether
use
antibiot
prophylaxi
select
agent
fine
balanc
calcul
risk
expect
benefit
risk
consid
includ
associ
fluoroquinolon
use
sever
clostridium
difficil
methicillinresist
staphylococcu
aureu
mrsa
advers
drug
reaction
antibiot
resist
whether
prophylaxi
preclud
use
quinolon
empir
therapi
neutropen
fever
patient
stratifi
low
risk
benefit
prophylact
antibiot
patient
subset
chemotherapyinduc
neutropenia
remain
controversi
regard
time
length
prophylaxi
guidelin
european
confer
infect
leukemia
ecil
suggest
start
chemotherapi
continu
resolut
neutropenia
initi
empir
antibacteri
therapi
febril
neutropenia
problem
gramposit
infect
particularli
due
streptococci
address
number
studi
use
differ
agent
includ
oral
penicillin
macrolid
rifampicin
rifampin
howev
given
mix
result
associ
emerg
resist
difficult
therefor
make
recommend
prophylaxi
gramposit
pathogen
use
levofloxacin
shown
benefit
center
advoc
prophylaxi
pneumococc
infect
allogen
hsct
recipi
function
asplen
patient
patient
receiv
immunosuppress
therapi
gvhd
pneumococc
isol
intermedi
highlevel
resist
rate
penicillin
approach
altern
agent
consid
base
local
suscept
pattern
trimethoprimsulfamethoxazol
prophylaxi
pn
jirovecii
like
protect
pneumococc
diseas
attempt
antifung
prophylaxi
met
variabl
success
initi
studi
examin
oral
polyen
nystatin
dose
unit
per
day
littl
effect
incid
invas
candidosi
neutropen
patient
wherea
amphotericin
b
superior
placebo
prevent
diseas
invas
candid
infect
thought
gain
entri
via
gut
nonabsorb
antifung
agent
protect
fungal
infect
site
name
skin
intraven
cathet
site
respiratori
tract
oral
system
activ
azol
potenti
control
colon
well
prevent
dissemin
ketoconazol
reduc
yeast
carriag
incid
local
system
candidosi
compar
placebo
nonabsorb
agent
absorpt
impair
neutropen
patient
particularli
bmt
recipi
breakthrough
infect
occur
ketoconazol
also
caus
elev
ciclosporin
level
result
activ
hepat
p
enzym
seriou
idiosyncrat
hepatotox
fluconazol
reduc
colon
mucos
thrush
number
dissemin
yeast
infect
two
placebocontrol
studi
hsct
recipi
show
signific
reduct
invas
fungal
infect
ifi
fluconazol
associ
reduc
mortal
fluconazol
prophylaxi
reduc
incid
ifi
overal
mortal
empir
antifung
therapi
allogen
hsct
recipi
autolog
hsct
recipi
unfortun
use
center
associ
increas
colon
infect
candida
krusei
intrins
resist
fluconazol
fluconazol
also
inact
import
invas
mold
affect
popul
especi
aspergillu
spp
zygomycet
contrast
itraconazol
activ
mold
particularli
aspergillu
spp
see
ch
howev
origin
capsul
formul
poorli
absorb
hsct
patient
overcom
introduct
itraconazolecyclodextrin
complex
solut
metaanalysi
shown
formul
associ
lower
overal
incid
fungal
infect
lower
mortal
fungal
infect
reduct
use
intraven
amphotericin
suspect
invas
fungal
infect
fluconazol
oral
amphotericin
placebo
also
reduct
incid
invas
aspergillosi
random
trial
involv
neutropen
patient
aml
md
prophylaxi
posaconazol
led
decreas
ifi
due
aspergillosi
reduc
overal
mortal
compar
compar
group
receiv
fluconazol
itraconazol
prophylaxi
similar
effect
shown
allogen
hsct
patient
gvhd
howev
posaconazol
prophylaxi
evalu
date
allogen
hsct
recipi
neutropen
period
post
condit
voriconazol
use
prophylaxi
although
larg
trial
data
use
set
still
await
extendedspectrum
triazol
prophylaxi
avoid
patient
receiv
vinca
alkaloidbas
chemotherapi
regimen
vincristin
acut
lymphoblast
leukemia
case
amphotericin
regimen
echinocandin
could
consid
micafungin
echinocandin
approv
prophylaxi
candid
infect
patient
undergo
hsct
random
doubleblind
trial
neutropen
autolog
allogen
hsct
recipi
compar
mg
per
day
micafungin
mg
per
day
fluconazol
antifung
prophylaxi
micafungin
superior
fluconazol
base
absenc
breakthrough
fungal
infect
absenc
trial
data
would
appropri
recommend
prophylaxi
continu
absolut
neutrophil
count
l
chemotherapi
patient
allogen
hsct
argument
continu
prophylaxi
least
day
end
immunosuppress
case
superven
gvhd
amphotericin
administ
nasal
spray
produc
conflict
result
prevent
invas
aspergillosi
although
studi
shown
greater
benefit
aerosol
one
studi
show
signific
differ
proven
probabl
possibl
invas
aspergillosi
aerosol
amphotericin
inhal
vs
prophylaxi
pn
jirovecii
infect
prove
remark
effect
undergo
treatment
acut
lymphoblast
leukaemia
first
month
postbmt
trimethoprimsulfamethoxazol
three
time
weekli
studi
although
unit
use
regimen
nebul
pentamidin
often
use
marrow
engraft
avoid
myelosuppress
effect
trimethoprimsulfamethoxazol
although
data
suggest
may
inferior
use
prophylact
allogen
transplant
recipi
altern
includ
dapson
atovaquon
viru
infect
neutropen
patient
due
reactiv
human
herp
virus
adult
patient
leukemia
herp
simplex
viru
hsv
seroposit
incid
hsv
infect
among
hsvseroposit
hsct
recipi
hsv
infect
patient
leukemia
subsequ
reactiv
latent
viru
case
aciclovir
acyclovir
mg
everi
h
mg
everi
h
effect
prophylaxi
hsv
infect
hsvseroposit
patient
leukemia
undergo
chemotherapi
bmt
recipi
altern
regimen
valaciclovir
mg
everi
h
chemoprophylaxi
cmv
infect
defin
use
antivir
agent
prevent
primari
cmv
infect
cmv
reactiv
investig
detail
hsct
recipi
although
cmv
diseas
also
occur
patient
acut
leukemia
receiv
chemotherapi
allogen
hsct
recipi
compris
group
highest
risk
cmv
reactiv
diseas
highdos
aciclovir
shown
partial
effect
prevent
cmv
infect
diseas
postbmt
multicent
random
trial
compar
mgm
intraven
everi
h
month
follow
mg
everi
h
mouth
month
mg
everi
h
oral
month
follow
placebo
incid
cmv
infect
reduc
surviv
increas
day
postbmt
although
rate
cmv
pneumonia
similar
two
group
valaciclovir
also
use
set
use
ganciclovir
prophylaxi
cmv
infect
shown
benefit
reduc
incid
cmv
diseas
effect
surviv
first
month
postbmt
preemptiv
therapi
defin
use
antivir
agent
asymptomat
patient
cmv
detect
screen
assay
includ
ganciclovir
valganciclovir
foscarnet
choic
depend
risk
toxic
antivir
drug
use
previous
weekli
monitor
allogen
hsct
recipi
use
cmv
antigenemia
assay
techniqu
detect
either
cmv
dna
rna
use
preemptiv
manag
cmv
infect
center
vari
regard
cutoff
valu
use
therapi
commenc
studi
progress
better
defin
ganciclovir
use
preemptiv
therapi
follow
detect
cmv
infect
surviv
improv
day
posttranspl
foscarnet
may
consid
secondlin
preemptiv
therapi
combin
cidofovir
consid
secondlin
preemptiv
therapi
mgkg
care
monitor
renal
function
requir
therapeut
option
patient
multiresist
cmv
diseas
leflunomid
artesun
howev
experi
agent
limit
date
evid
support
use
prophylaxi
human
herpesviru
hhv
infect
follow
hsct
summari
prophylact
regimen
shown
tabl
use
empir
antibiot
therapi
febril
neutropen
patient
almost
univers
practic
await
microbiolog
diagnosi
associ
high
mortal
particularli
patient
gramneg
bacteremia
trigger
usual
singl
oral
temperatur
two
separ
temperatur
least
h
apart
regimen
chosen
activ
common
organ
like
result
overwhelm
sepsi
death
influenc
local
antibiot
sensit
pattern
incid
particular
infect
specif
need
patient
prophylact
regimen
use
tradit
signific
organ
enterobacteriacea
ps
aeruginosa
carri
mortal
earlier
regimen
includ
aminoglycosid
combin
antibiot
attempt
achiev
broadspectrum
synergist
activ
organ
ps
aeruginosa
aminoglycosid
use
carri
inher
risk
renal
ototox
data
combin
empir
therapi
conflict
nation
comprehens
cancer
network
nccn
guidelin
recommend
aminoglycosid
patient
high
risk
pseudomon
infect
histori
previou
pseudomon
infect
presenc
ecthyma
gangrenosum
wherea
infecti
diseas
societi
america
idsa
guidelin
suggest
may
ad
case
progress
infect
document
resist
gramneg
infect
cochran
review
random
control
trial
conclud
primari
outcom
measur
allcaus
mortal
signific
differ
monotherapi
combin
rr
second
outcom
measur
treatment
failur
advantag
monotherapi
trial
compar
differ
patient
document
infect
hematolog
malign
rr
differ
two
compar
arm
number
superinfect
significantli
advers
event
combin
group
nephrotox
anoth
metaanalysi
also
conclud
monotherapi
effect
combin
data
patient
nonneutropen
studi
shown
oncedaili
dose
aminoglycosid
regimen
efficaci
multipledos
regimen
first
studi
doubl
therapi
gave
result
inferior
aminoglycosidecontain
regimen
later
studi
use
ceftazidim
latamoxef
cefoperazon
combin
ureidopenicillin
conclud
combin
equal
efficaci
less
nephrotox
aminoglycosidecontain
regimen
howev
unclear
whether
better
monotherapi
number
antibiot
regimen
subsequ
evalu
empir
therapi
febril
neutropen
patient
list
box
report
stenotrophomona
maltophilia
select
carbapenem
intrins
resist
addit
concern
central
nervou
system
cn
toxic
highdos
imipenem
patient
receiv
ciprofloxacin
prophylaxi
one
advantag
carbapenem
activ
streptococci
allow
use
alon
without
need
earli
glycopeptid
therapi
similar
streptococc
activ
provid
piperacillintazobactam
recent
metaanalysi
random
trial
examin
choic
agent
empir
therapi
treatment
febril
neutropenia
report
cefepim
associ
increas
allcaus
mortal
increas
infectionrel
mortal
author
conclud
ceftazidim
imipenem
meropenem
piperacillintazobactam
suitabl
monotherapi
agent
high
incid
gramposit
infect
suggest
empir
therapi
contain
broadspectrum
antigramposit
agent
clinic
trial
glycopeptid
provid
conflict
evid
whether
add
agent
earli
studi
center
signific
number
gramposit
infect
show
initi
vancomycin
teicoplanin
increas
respons
rate
reduc
morbid
although
studi
show
reduct
mortal
addit
vancomycin
associ
increas
toxic
larg
joint
studi
conduct
eortc
nation
cancer
institut
canada
show
includ
vancomycin
initi
therapi
confer
addit
benefit
reinforc
metaanalysi
show
benefit
empir
gramposit
therapi
either
initi
persist
fever
increas
isol
vancomycinresist
enterococci
vre
prompt
center
diseas
control
prevent
cdc
issu
guidelin
use
vancomycin
specif
exclud
use
empir
therapi
neutropen
patient
seem
prudent
although
idsa
suggest
vancomycin
may
use
initi
regimen
institut
fulmin
gramposit
infect
common
particularli
mrsa
may
problem
discontinu
day
later
infect
identifi
also
evid
choic
broadspectrum
agent
empir
therapi
influenc
emerg
glycopeptideresist
enterococci
gre
present
glycopeptideintermedi
staph
aureu
gisa
infect
signific
problem
uk
provid
anoth
reason
select
use
glycopeptid
institut
occur
oxazolidinon
linezolid
streptogramin
quinupristindalfopristin
daptomycin
altern
patient
intoler
vancomycin
teicoplanin
treatment
gre
gisa
infect
multicent
random
studi
febril
neutropen
patient
compar
safeti
linezolid
vancomycin
show
clinic
success
rate
day
complet
therapi
equival
mortal
day
complet
therapi
drug
advers
event
frequent
vancomycin
arm
time
defervesc
shorter
linezolid
arm
patient
document
gramposit
infect
slower
time
neutrophil
recoveri
seen
linezolid
arm
may
secondari
myelosuppress
effect
linezolid
statist
signific
durat
treatment
studi
independ
sinc
first
eortc
trial
evid
suggest
prolong
treatment
associ
superinfect
often
fungal
improv
outcom
current
eortc
trial
conduct
basi
discontinu
antibiot
day
minimum
treatment
four
consecut
afebril
day
similar
idsa
nccn
guidelin
day
without
fever
recommend
option
summar
tabl
health
servic
move
toward
earlier
discharg
group
patient
attempt
made
achiev
neutropen
popul
talcott
colleagu
deriv
risk
assess
model
patient
divid
four
group
fourth
group
found
low
risk
studi
subsequ
trial
show
amoxicillinclavulan
plu
ciprofloxacin
effect
intraven
ceftazidim
ceftriaxon
plu
amikacin
treat
patient
exampl
outpati
oralintraven
regimen
includ
box
approxim
febril
patient
remain
persist
neutropen
fail
respond
appar
appropri
antibiot
therapi
remain
febril
recoveri
neutrophil
count
irrespect
antimicrobi
therapi
administ
mani
patient
persist
fever
occult
fungal
infect
patient
acut
leukemia
allogen
hsct
recipi
highest
risk
due
prolong
neutropenia
immunosuppress
gvhd
autopsi
studi
shown
neutropen
patient
die
undiagnos
fungal
infect
view
difficulti
diagnosi
use
empir
antifung
therapi
advoc
recent
ecil
guidelin
consist
viewpoint
current
british
committe
standard
haematolog
bcsh
guidelin
advoc
empir
antifung
therapi
ifi
suspect
conjunct
highresolut
comput
tomographi
hrct
scan
mycolog
test
see
ch
main
random
studi
empir
antifung
therapi
base
compar
effect
amphotericin
mgkg
per
day
equival
treatment
patient
remain
febril
day
empir
therapi
although
respond
amphotericintr
group
effect
signific
patient
given
antifung
prophylaxi
vs
p
follow
number
agent
shown
least
effect
convent
amphotericin
liposom
amphotericin
b
ambisom
less
nephrotox
convent
amphotericin
least
effect
render
patient
afebril
associ
significantli
fewer
breakthrough
fungal
infect
subsequ
caspofungin
shown
least
effect
ambisom
set
patient
deterior
first
h
empir
therapi
pose
particularli
difficult
therapeut
challeng
import
gap
spectrum
select
regimen
deterior
may
due
gramneg
gramposit
organ
streptococci
may
caus
featur
similar
sepsi
syndrom
includ
acut
respiratori
distress
syndrom
septic
shock
enterococci
gramneg
activ
includ
antipseudomon
activ
essenti
consequ
addit
aminoglycosid
initi
monotherapi
recommend
also
support
ecil
guidelin
patient
septic
shock
glycopeptid
also
consid
approach
summar
figur
neutropen
patient
undergo
chemotherapi
indwel
central
line
commonli
becom
infect
predomin
pathogen
coagulaseneg
staphylococci
staph
aureu
other
includ
candida
spp
coryneform
acinetobact
stenotrophomona
pseudomona
spp
ideal
infect
cathet
remov
coagulaseneg
staphylococc
infect
may
effect
suppress
elimin
administ
antibiot
via
cathet
neutropenia
resolv
fig
algorithm
initi
manag
febril
neutropen
patient
receiv
prophylaxi
glycopeptid
frequent
vancomycin
given
chanc
success
resolut
bacteremia
fever
similar
respons
rate
obtain
coryneform
infect
due
candida
spp
enterobacteriacea
staph
aureu
ps
aeruginosa
acinetobact
sten
maltophilia
nontubercul
mycobacteria
form
tunnel
infect
requir
cathet
remov
appropri
antimicrobi
therapi
administ
presenc
port
infect
septic
phlebiti
associ
longterm
indwel
cathet
also
indic
cathet
remov
antimicrobi
therapi
pulmonari
infiltr
commonli
occur
febril
neutropen
patient
number
caus
especi
bmt
recipi
includ
noninfect
condit
pulmonari
edema
alveolar
hemorrhag
advers
drug
reaction
radiat
injuri
idiopath
pneumon
syndrom
focal
lesion
indic
fungal
infect
hrct
mri
scan
may
reveal
characterist
featur
clinic
statu
permit
caus
organ
may
obtain
bronchoalveolar
lavag
howev
mani
case
treatment
given
empir
initi
therapi
certainli
includ
agent
effect
common
respiratori
pathogen
str
pneumonia
haemophilu
influenza
well
gramneg
organ
includ
ps
aeruginosa
henc
carbapenem
piperacillintazobactam
ceftazidim
without
aminoglycosid
recommend
atyp
pneumonia
extrem
uncommon
popul
unless
particular
clinic
epidemiolog
reason
suggest
legionnair
diseas
erythromycin
omit
initi
therapi
unless
infect
appear
commun
relat
mycobacteri
infect
may
occasion
complic
hematolog
malign
patient
lymphoid
malign
bmt
recipi
receiv
trimethoprimsulfamethoxazol
prophylaxi
risk
pn
jirovecii
pneumon
empir
highdos
trimethoprimsulfamethoxazol
therapi
mgkg
per
day
divid
dose
warrant
patient
bmt
recipi
particularli
risk
cmv
pneumon
posttranspl
howev
cmv
pn
jirovecii
pneumon
usual
present
month
posttranspl
patient
longer
neutropen
time
present
taken
account
decis
made
regard
empir
therapi
cmv
pneumon
treat
intraven
ganciclovir
mgkg
everi
h
plu
intraven
immunoglobulin
mgkg
altern
day
day
despit
mortal
cmv
pneumon
still
excess
bmt
recipi
furthermor
myelosuppress
effect
ganciclovir
present
particular
problem
patient
patient
discharg
commun
risk
respiratori
viral
infect
agent
respiratori
syncyti
viru
influenza
paramyxovirus
occasion
caus
outbreak
hematolog
unit
despit
recent
advanc
diagnosi
treatment
invas
fungal
infect
ifi
failur
rate
approach
invas
aspergillosi
case
fatal
rate
hsct
leukemia
patient
quot
mortal
rate
candidemia
hematolog
malign
current
bcsh
guidelin
advoc
use
caspofungin
liposom
amphotericin
empir
therapi
suspect
ifi
lowest
rate
toxic
equal
efficaci
also
keep
current
ecil
guidelin
option
includ
voriconazol
posaconazol
therapi
fungal
infect
consid
detail
chapter
trend
toward
nonalbican
speci
c
glabrata
c
krusei
display
decreas
suscept
resist
azol
document
europ
north
america
speci
respons
invas
candid
infect
patient
hematolog
malign
recent
trial
three
licens
echinocandin
caspofungin
micafungin
anidulafungin
demonstr
respons
rate
excess
consid
among
firstlin
agent
invas
candid
infect
especi
speci
known
patient
receiv
azol
prophylaxi
sever
sepsi
support
guidelin
updat
idsa
candida
guidelin
togeth
use
ambisom
lipid
formul
amphotericin
voriconazol
altern
agent
use
care
patient
previou
azol
prophylaxi
use
recommend
durat
therapi
consist
day
follow
last
posit
blood
cultur
togeth
extens
investig
dissemin
infect
trial
regard
use
efungumab
mycograb
human
recombin
antibodi
consist
fv
fragment
bind
domain
structur
candida
spp
need
recommend
regard
use
combin
antifung
made
current
licens
mortal
due
invas
aspergillosi
remain
high
neutropen
patient
infect
import
caus
death
childhood
aml
adult
bmt
recipi
bmt
recipi
case
fatal
rate
high
success
outcom
depend
upon
earli
treatment
consider
extent
bone
marrow
recoveri
agent
activ
aspergillu
spp
includ
amphotericin
deoxychol
lipidassoci
prepar
extendedspectrum
triazol
echinocandin
highdos
convent
amphotericin
also
associ
high
incid
nephrotox
lipidassoci
formul
drug
licens
use
patient
fail
treatment
experienc
unaccept
toxic
convent
amphotericin
liposom
amphotericin
ambisom
studi
random
prospect
trial
compar
two
dose
mgkg
per
day
mgkg
per
day
treatment
invas
aspergillosi
neutropen
patient
mortal
approxim
attribut
mortal
around
two
arm
doubleblind
comparison
ambisom
mgkg
ambisom
mgkg
primari
therapi
corn
colleagu
demonstr
addit
benefit
mgkg
dose
mgkg
dose
liposom
amphotericin
b
voriconazol
assess
den
colleagu
two
openlabel
studi
respons
rate
report
respect
superior
voriconazol
amphotericin
deoxychol
term
efficaci
safeti
surviv
demonstr
herbrecht
colleagu
random
trial
superior
irrespect
host
group
site
lesion
neutropen
statu
voriconazol
given
highest
grade
recommend
recent
guidelin
updat
follow
ambisom
north
america
nccn
current
recommend
voriconazol
agent
choic
firstlin
therapi
invas
pulmonari
aspergillosi
insuffici
data
recommend
use
caspofungin
itraconazol
posaconazol
agent
firstlin
therapi
invas
aspergillosi
use
salvag
therapi
similar
efficaci
also
current
insuffici
data
recommend
combin
therapi
firstlin
therapi
one
retrospect
studi
compar
combin
voriconazol
caspofungin
given
salvag
therapi
failur
amphotericin
formul
allogen
hsct
recipi
voriconazol
monotherapi
histor
control
group
demonstr
substanti
improv
surviv
develop
mycot
lung
sequestra
mistakenli
term
mycetoma
may
requir
addit
therapi
lesion
appear
bone
marrow
regener
patient
risk
lifethreaten
hemoptysi
addit
patient
requir
chemotherapi
bone
marrow
transplant
consider
risk
relaps
origin
infect
resect
lesion
shown
effect
prevent
relaps
follow
bone
marrow
transplant
associ
lower
mortal
antifung
therapi
alon
studi
although
larg
random
studi
set
hematopoiet
growth
factor
extens
use
treat
neutropen
patient
studi
consist
shown
granulocytecolonystimul
factor
gcsf
reduc
durat
neutropenia
howev
reduct
infecti
complic
modest
trial
unabl
demonstr
reduct
infecti
morbid
mortal
probabl
major
effect
gcsf
acceler
recoveri
neutrophil
wherea
impact
critic
lag
period
profound
neutropenia
american
societi
oncolog
nccn
publish
guidelin
use
agent
set
anticanc
chemotherapi
granulocytemacrophag
colonystimul
factor
gmcsf
macrophag
colonystimul
factor
mcsf
may
benefici
treatment
invas
fungal
infect
although
largescal
trial
demonstr
regrett
still
lack
renew
interest
shown
modal
coupl
improv
method
harvest
increas
yield
follow
use
growth
factor
routin
prophylact
use
intraven
immunoglobulin
reduc
viral
infect
howev
addit
intraven
immunoglobulin
ganciclovir
may
improv
surviv
cmv
pneumon
postexposur
immunoglobulin
indic
prevent
hepat
measl
varicellazost
infect
sinc
first
success
human
cadaver
kidney
transplant
solid
organ
transplant
proceed
becom
viabl
option
manag
endorgan
failur
worldwid
current
graft
surviv
cadaver
nonextend
criteria
donor
renal
transplant
usa
respect
result
similar
europ
develop
surgeri
better
control
reject
infect
complic
allow
steadi
improv
surviv
organ
graft
transplant
unit
use
tripl
regimen
azathioprin
mycophenol
calcineurin
inhibitor
ciclosporin
corticosteroid
immunosuppress
azathioprin
purin
analog
inhibit
band
tcell
prolifer
consequ
cellmedi
immun
cmi
humor
immun
inhibit
drug
may
take
week
month
exert
full
effect
ciclosporin
calcineurin
inhibitor
arrest
lymphocyt
cell
cycl
rest
phase
effect
cell
minim
effect
b
cell
result
effect
suppress
cmi
littl
effect
humor
immun
effect
phagocytosi
inflammatori
respons
preserv
corticosteroid
high
dose
broad
immunosuppress
action
produc
reduct
antigenstimul
lymphocyt
prolifer
blunt
primari
antibodi
respons
also
inhibit
neutrophil
chemotaxi
monocyt
phagocytosi
dramat
reduc
inflammatori
respons
high
dosag
disguis
presenc
infect
aim
regimen
achiev
balanc
graft
reject
risk
infect
episod
subsequ
acut
reject
requir
consider
immunosuppress
accompani
increas
risk
opportunist
infect
phase
acut
reject
vari
length
differ
transplant
episod
occur
first
month
liver
transplant
wherea
phase
acut
reject
last
month
renal
transplant
reject
episod
usual
treat
highdos
methylprednisolon
variou
antibodi
prepar
polyclon
antithymocyt
globulin
atg
antilymphocyt
globulin
alg
pantcel
monoclon
antibodi
patient
requir
second
third
graft
usual
even
immunosuppress
increas
risk
opportunist
infect
tacrolimu
anoth
calcineurin
antagonist
substitut
ciclosporin
certain
indic
sever
studi
demonstr
fewer
infect
complic
may
consequ
need
less
episod
antireject
therapi
mycophenol
mofetil
inhibitor
inosin
monophosph
dehydrogenas
inhibit
purin
synthesi
use
substitut
calcineurin
inhibitor
although
associ
renal
toxic
allow
improv
renal
function
studi
shown
result
increas
risk
reject
recent
review
compar
use
azathioprin
mycophenol
liver
transplant
conclud
date
littl
clinic
benefit
could
observ
mycophenol
mofetil
azathioprin
still
consider
scope
refin
immunosuppress
new
agent
hope
enabl
reduct
infect
complic
risk
infect
organ
transplant
patient
influenc
previou
epidemiolog
exposur
degre
immunosuppress
epidemiolog
exposur
divid
donorderiv
infect
recipientderiv
infect
nosocomi
infect
commun
infect
extent
immunosuppress
determin
type
immunosuppress
therapi
dose
durat
see
box
underli
diseas
comorbid
condit
presenc
devit
tissu
fluid
collect
transplant
organ
presenc
invas
devic
import
factor
includ
concomit
infect
immunomodul
virus
cmv
human
herp
virus
hepat
b
c
virus
infecti
complic
follow
rel
predict
chronolog
order
transplant
procedur
knowledg
help
guid
use
durat
prophylaxi
establish
diagnosi
appropri
investig
administ
empir
treatment
necessari
summar
figur
first
month
transplant
infect
larg
associ
transplant
surgic
procedur
particularli
complic
anastomos
associ
specif
procedur
infect
transmit
allograft
present
recipi
transplant
import
compon
pretranspl
evalu
recogn
treat
infect
nosocomi
infect
due
vre
mrsa
clostridium
difficil
coliti
also
import
time
first
sixth
month
follow
transplant
import
infect
caus
herp
group
virus
especi
cmv
nocardia
speci
listeria
monocytogen
toxoplasma
gondii
pn
jirovecii
fungi
addit
latent
infect
tuberculosi
histoplasmosi
may
reactiv
time
risk
infect
correl
sever
immunosuppress
requir
treat
reject
episod
subsequ
infect
usual
result
communityacquir
organ
patient
suffer
chronic
viral
infect
affect
graft
other
intens
immunosuppress
remain
risk
opportunist
infect
rare
infect
late
posttranspl
period
describ
includ
chronic
infect
hepat
e
viru
caus
cirrhosi
late
complic
bacteri
infect
occur
approxim
renal
transplant
recipi
liver
transplant
patient
seri
patient
suffer
least
one
bacteri
infect
posttranspl
period
common
infect
intraabdomin
abscess
cholang
bacteremia
wound
infect
lower
respiratori
tract
infect
urinari
tract
infect
intraabdomin
infect
respons
approxim
liver
transplant
overal
mortal
less
vari
accord
site
organ
subsequ
resist
organ
becom
establish
endem
pathogen
mani
transplant
unit
mrsa
found
lead
caus
bacteremia
liver
transplant
recipi
one
center
respons
episod
vre
extendedspectrum
gramneg
organ
also
increasingli
caus
infect
patient
repres
organ
isol
infect
patient
postop
period
shown
box
bacteria
isol
graft
perfus
fluid
differ
propens
caus
posttransplant
infect
posit
cultur
found
case
renal
transplant
due
gramposit
skin
bacteria
seem
seriou
consequ
howev
isol
enterobacteriacea
ps
aeruginosa
correl
vascular
infect
postop
sepsi
warrant
system
antibiot
therapi
follow
transplant
infect
due
nocardia
spp
import
late
complic
follow
transplant
usual
occur
first
month
correl
degre
immunosuppress
outbreak
renal
transplant
unit
describ
incid
group
tuberculosi
tend
occur
sever
month
transplant
onset
significantli
later
renal
transplant
group
organ
transplant
recipi
approxim
onethird
dissemin
infect
overal
mortal
overal
incid
mycobacteri
infect
transplant
popul
greater
incid
gener
popul
transplant
recipi
increas
risk
legionnair
diseas
virtu
immunosuppress
addit
uk
studi
demonstr
legionella
spp
could
isol
water
approxim
transplant
unit
legionella
control
import
compon
water
air
condit
manag
hospit
colon
yeast
common
popul
although
incid
vari
accord
number
frequenc
site
sampl
use
antifung
prophylaxi
infect
rate
vari
lowest
renal
transplant
recipi
approxim
incid
fungal
infect
fall
possibl
consequ
reduc
immunosuppress
improv
surgic
techniqu
infect
caus
candida
spp
approxim
aspergillu
spp
account
major
invas
mold
infect
pn
jirovecii
pneumon
occur
kidney
liver
heart
heartlung
lung
transplant
recipi
routin
prophylaxi
implement
close
link
cmv
diseas
candid
infect
associ
death
invas
aspergillosi
almost
univers
fatal
group
site
infect
transplant
depend
thu
urinari
tract
candidosi
mostli
confin
renal
transplant
group
lung
transplant
recipi
much
increas
risk
pulmonari
infect
although
occur
infrequ
focal
brain
infect
solid
organ
transplant
patient
almost
exclus
due
fungi
usual
aspergillu
spp
cryptococcu
neoforman
frequent
caus
mening
fungal
infect
occur
first
month
transplant
although
pn
jirovecii
infect
tend
delay
cryptococcosi
usual
affect
patient
late
transplant
period
infect
due
endem
fungi
includ
coccidioid
immiti
often
follow
exposur
southwestern
unit
state
histoplasma
capsulatum
often
follow
exposur
ohio
river
valley
also
elsewher
world
blastomyc
dermatitidi
may
also
seen
late
posttranspl
period
one
seri
median
time
symptom
histoplasmosi
month
transplant
manag
infect
discuss
chapter
sinc
earliest
day
transplant
viru
infect
caus
problem
transplant
recipi
member
herpesvirida
commonli
implic
cytomegaloviru
respons
greatest
number
type
infect
patient
incid
vari
reflect
incid
seroposit
among
recipi
popul
number
seroposit
seroneg
transplant
howev
incid
diseas
transplant
depend
lowest
renal
transplant
recipi
symptomat
less
overal
infect
patient
develop
diseas
although
highest
risk
seroposit
seroneg
transplant
develop
clinic
diseas
site
diseas
transplant
depend
focus
graft
transplant
recipi
affect
develop
cmv
pneumon
posttranspl
hepat
occur
solid
organ
transplant
recipi
overal
common
caus
hepat
c
viru
hcv
liver
transplant
patient
infect
occur
result
reinfect
patient
transplant
hcvrelat
cirrhosi
polymeras
chain
reaction
pcr
techniqu
shown
virtual
infect
patient
suffer
reinfect
posttranspl
univers
screen
blood
donor
awar
donor
statu
primari
hcv
infect
occur
incid
much
lower
one
studi
patient
pretranspl
infect
develop
posttranspl
hepat
mostli
due
hcv
reinfect
hepat
b
viru
hbv
follow
liver
transplant
almost
inevit
unless
longterm
prophylaxi
use
highest
recurr
seen
hbvdna
posit
transplant
epsteinbarr
viru
ebv
infect
follow
transplant
probabl
underdiagnos
clinic
diseas
due
reactiv
although
primari
infect
occur
usual
patient
discharg
respons
sever
diseas
import
complic
ebv
infect
posttranspl
lymphoprolif
disord
ptld
overal
incid
condit
approxim
larg
seri
variou
solid
organ
graft
recipi
viremia
found
primari
viremia
develop
ptld
compar
secondari
viremia
case
risk
diseas
also
increas
use
antireject
therapi
antitcel
antibodi
advent
aciclovir
hsv
infect
almost
exclus
consequ
reactiv
respons
clinic
diseas
approxim
seroposit
patient
hsv
infect
much
less
clinic
signific
herp
group
infect
human
may
respons
central
nervou
system
diseas
post
transplant
cn
symptom
occur
liver
transplant
recipi
viremia
compar
without
infect
may
also
immunomodulatori
role
associ
increas
risk
cmv
infect
fungal
infect
human
transmit
donor
recipi
result
kaposi
sarcoma
case
seroconvert
polyomaviru
caus
latent
infect
kidney
immunocompet
subject
renal
transplant
recipi
may
respons
tubulointerstiti
nephriti
graft
dysfunct
incid
toxoplasmosi
vari
accord
type
transplant
common
heart
transplant
recipi
seroneg
patient
receiv
heart
seroposit
donor
seroconvert
addit
toxoplasmosi
govern
seropreval
infect
uk
higher
countri
franc
serolog
statu
donor
recipi
highest
rate
sever
infect
occur
transplant
seroposit
donor
seroneg
recipi
renal
transplant
recipi
less
develop
primari
toxoplasmosi
case
occur
within
month
transplant
character
enceph
brain
abscess
retin
pneumon
cardiac
involv
hepat
chemoprophylaxi
antimicrobi
prophylaxi
along
vaccin
preemptiv
therapi
form
mainstay
prevent
strategi
infect
recent
prophylact
regimen
use
transplant
recipi
base
risk
infect
like
organ
regimen
shown
effect
neutropen
patient
surgic
prophylaxi
adopt
yet
subject
random
compar
trial
short
cours
prophylact
antibiot
probabl
appropri
prevent
wound
infect
relat
procedur
select
decontamin
digest
tract
may
benefit
transplant
group
although
conflict
evid
gramneg
infect
reduc
liver
transplant
recipi
increas
gramposit
infect
includ
mrsa
vre
seen
sever
heart
transplant
center
number
studi
demonstr
benefit
longterm
prophylaxi
urinari
tract
infect
renal
transplant
recipi
trimethoprimsulfamethoxazol
mg
nightli
ciprofloxacin
effect
although
former
addit
benefit
prevent
pn
jirovecii
infect
issu
mycobacteri
prophylaxi
remain
controversi
polici
vari
intern
signific
risk
isoniazid
hepat
toxic
drug
use
select
howev
risk
vari
accord
transplant
renal
transplant
recipi
liver
transplant
recipi
patient
prophylaxi
justifi
asian
highrisk
ethnic
origin
histori
tuberculosi
radiograph
chang
suggest
past
chest
infect
high
risk
fungal
infect
liver
transplant
recipi
led
administr
antifung
agent
posttranspl
period
nonabsorb
agent
amphotericin
nystatin
sometim
combin
oral
antibiot
gentamicin
polymyxin
b
wide
use
fluconazol
itraconazol
studi
random
compar
trial
liver
transplant
better
placebo
prevent
superfici
invas
candidosi
prophylaxi
pn
jirovecii
pneumonia
trimetho
primsulfamethoxazol
probabl
necessari
first
year
posttranspl
except
lung
transplant
recipi
signific
persist
risk
diseas
current
american
societi
transplant
guidelin
recommend
antivir
prophylaxi
cmv
donorposit
recipientneg
solid
organ
transplant
recipi
sever
random
compar
studi
demonstr
earli
first
day
discharg
posttranspl
ganciclovir
without
gammaglobulin
effect
aciclovir
variou
dose
prevent
cmv
symptomat
infect
liver
transplant
symptomat
infect
reduc
preemptiv
prophylaxi
target
patient
highest
risk
diseas
limit
durat
drug
administr
reduc
toxic
cost
henc
kidneypancrea
transplant
patient
receiv
pantcel
monoclon
antibodi
therapi
cmvshed
liver
transplant
recipi
appear
benefit
preemptiv
prophylaxi
ganciclovir
foscarnet
cmv
antigenemia
pcrguid
preemptiv
therapi
base
attain
predefin
viral
load
effect
less
expens
univers
oral
ganciclovir
prophylaxi
day
intraven
ganciclovir
day
durat
preemptiv
therapi
fix
determin
viral
load
vari
length
center
trial
prophylaxi
lamivudin
prevent
recurr
hbv
follow
liver
transplant
shown
although
hbvdna
level
becom
undetect
virtual
patient
effect
sustain
emerg
resist
mutant
consequ
altern
strategi
involv
combin
adefovir
lamivudin
hepat
b
immun
globulin
employ
although
transplant
recipi
sever
immunocompromis
pauciti
sign
neutropen
patient
face
seriou
sepsi
immedi
postop
period
behav
like
nontranspl
patient
surgic
sepsi
consequ
concept
earli
empir
therapi
respons
fever
alon
appli
patient
attempt
made
identifi
focu
sepsi
noninfect
caus
fever
transplant
patient
antimicrobi
therapi
may
reason
withheld
patient
otherwis
well
identifi
infect
caus
kept
review
empir
treatment
consid
necessari
choic
antimicrobi
govern
time
infect
henc
probabl
organ
type
transplant
site
sepsi
knowledg
colon
resist
organ
mrsa
vre
local
antimicrobi
resist
pattern
discuss
previous
fungal
infect
manag
use
agent
use
neutropen
patient
antifung
contraind
care
requir
use
toxic
especi
renal
liver
transplant
recipi
drug
interact
especi
flucytosin
antimetabolit
triazol
ciclosporin
tacrolimu
see
probabl
appropri
reduc
immunosuppress
face
progress
lifethreaten
fungal
infect
invas
aspergillosi
especi
set
nonessenti
organ
graft
kidney
transplant
although
evid
benefit
anecdot
attempt
immunomodul
includ
use
colonystimul
factor
gcsf
antagon
effect
triazol
immunocompromis
mous
model
invas
aspergillosi
gmcsf
use
success
neutropen
patient
might
prove
use
gcsf
transplant
set
patient
present
pulmonari
infiltr
fever
month
posttranspl
like
cmv
pn
jirovecii
infect
unless
receiv
trimethoprimsulfamethoxazol
prophylaxi
infect
manag
hsct
recipi
possibl
communityacquir
respiratori
tract
infect
includ
due
influenza
respiratori
syncyti
virus
alway
born
mind
incid
occur
renal
transplant
recipi
relat
degre
immunosuppress
seen
particularli
patient
receiv
like
primari
ebv
infect
present
mainstay
therapi
reduct
immunosuppress
togeth
intraven
aciclovir
mgkg
everi
h
howev
mani
patient
requir
local
resect
radiotherapi
affect
tissu
andor
antilymphoma
chemotherapi
develop
field
includ
possibl
immunotherapi
mean
donor
leukocyt
infus
recent
efficaci
rituximab
monoclon
antibodi
treatment
ebvdriven
ptld
describ
ciclosporin
tacrolimu
metabol
cytochrom
p
enzym
system
therefor
interact
number
import
antimicrobi
agent
like
prescrib
transplant
recipi
tabl
level
drug
may
alter
induct
inhibit
system
essenti
measur
prevent
toxic
well
avoid
inadequ
excess
immunosuppress
consequ
reject
infect
rifampicin
potent
induc
cytochrom
isoenzym
caus
increas
metabol
ciclosporin
tacrolimu
well
reduc
bioavail
corticosteroid
erythromycin
newer
macrolid
particularli
clarithromycin
azol
antifung
agent
especi
ketoconazol
itraconazol
voriconazol
fluconazol
high
dose
competit
inhibit
pathway
thu
increas
level
ciclosporin
tacrolimu
renal
function
often
impair
transplant
set
may
complex
interact
ciclosporin
potenti
nephrotox
particularli
initi
therapi
nephrotox
antimicrobi
agent
aminoglycosid
highdos
trimethoprimsulfamethoxazol
vancomycin
amphotericin
therapeut
drug
monitor
mandatori
except
amphotericin
prevent
addit
toxic
altern
agent
chosen
whenev
possibl
tabl
prevent
alway
goal
manag
infect
complic
neutropenia
organ
transplant
becom
increasingli
import
past
decad
advent
mrsa
vre
resist
organ
despit
develop
antimicrobi
good
activ
infect
agent
mortal
mani
infect
remain
high
spectrum
immunocompromis
patient
chang
evolut
chemotherapi
stemcel
transplant
immunosuppress
regimen
tissu
organ
transplant
techniqu
thu
expect
see
pattern
opportunist
infect
shift
well
